Naples

• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended recruitment
  2023-506842-22-00 7 2025-05-19 Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended recruitment
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
• A trial of Lu AF82422 in Participants with Multiple System Atrophy (MSA) Ended recruitment
  2024-517169-18-00 5 2025-04-10 Multiple System Atrophy
• BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part … Ended recruitment
  2024-515740-23-00 5 2025-03-25 Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
• A study to assess efficacy and safety of efgartigimod PH20 SC in adults with ocular myasthenia gravis Ended recruitment
  2024-514133-38-00 5 2025-03-19 Ocular Myasthenia Gravis
• Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study Ended recruitment
  2024-512180-31-00 4 2025-03-14 Oligometastatic renal cell carcinoma
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended recruitment
  2024-512946-41-00 5 2025-03-05 Menstrual Migraine
• A study to investigate improvement in pruritus of Lichen Simplex Chronicus with dupilumab injections compared with placebo in male and fema … Ended recruitment
  2024-514762-39-00 5 2025-03-03 Neurodermatitis
• Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Ended recruitment
  2024-515538-34-00 10 2025-02-27 Head and Neck Squamous Cell Carcinoma
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• FINESSE: Research on improving albuminuria in patients with chronic kidney disease through the use of finerenone and semaglutide. Ended recruitment
  2023-506434-69-00 4 2025-02-11 Chronic Kidney Disease
• A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Partic … Ended recruitment
  2023-509588-25-00 4 2025-02-11 Hepatitis B
• PENTALLO (PENTAglobin in Acute Leukemia and ALLOgeneic transplants) Ended recruitment
  2024-518940-19-02 4 2025-01-28 Acute Myeloid Leukemia (AML)
• Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surger … Ended recruitment
  2024-516316-13-00 4 2025-01-21 Merkel cell carcinoma without metastases in other organs and surgicall
• A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas … Ended recruitment
  2023-508276-11-00 5 2025-01-17 Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal J
• A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants with Pulmonary Hypertension … Ended recruitment
  2024-513991-16-00 4 2025-01-17 Pulmonary Hypertension Associated with Interstitial Lung Disease
• A study to investigate the course of synovial hypertrophy in patients with haemophilia A on efanesoctocog alfa prophylaxis Ended recruitment
  2024-512066-33-00 6 2024-12-19 Haemophilia A
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513208-32-00 5 2024-12-16 Chronic Spontaneous Urticaria
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia Ended recruitment
  2024-518669-83-00 4 2024-12-05 acute promyelocytic leukemia (APL) in children and adolescents
• Potential protective role of SGLT-2 inhibitors for chemotherapy-induced cardiotoxicity (PROTECT trial) Ended recruitment
  2024-518611-18-00 4 2024-12-03 Chemotherapy-induced cardiotoxicity in breast cancer
• A study to test whether BI 764524 helps people with an eye condition called diabetic retinopathy Ended recruitment
  2023-508891-12-00 4 2024-11-28 Diabetic retinopathy

Showing 625–648 of 1,177 trials